Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations …

H Van Poppel, MJ Roobol, CR Chapple, JWF Catto… - European Urology, 2021 - Elsevier
Background Recommendations against prostate-specific antigen (PSA) testing in 2012 have
increased advanced-stage diagnosis and prostate cancer–specific mortality rates. Objective …

Magnetic nanoparticles in nanomedicine: a review of recent advances

K Wu, D Su, J Liu, R Saha, JP Wang - Nanotechnology, 2019 - iopscience.iop.org
Nanomaterials, in addition to their small size, possess unique physicochemical properties
that differ from bulk materials, making them ideal for a host of novel applications. Magnetic …

[HTML][HTML] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

HU Ahmed, AES Bosaily, LC Brown, R Gabe, R Kaplan… - The Lancet, 2017 - thelancet.com
Background Men with high serum prostate specific antigen usually undergo transrectal
ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects …

Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer

FJH Drost, DF Osses, D Nieboer… - Cochrane Database …, 2019 - cochranelibrary.com
Background Multiparametric magnetic resonance imaging (MRI), with or without MRI‐
targeted biopsy, is an alternative test to systematic transrectal ultrasonography‐guided …

Multiparametric MRI for prostate cancer diagnosis: current status and future directions

A Stabile, F Giganti, AB Rosenkrantz, SS Taneja… - Nature reviews …, 2020 - nature.com
The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and
consequent overtreatment as well as underdiagnosis and missed diagnoses in many men …

EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent

N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane …

FJH Drost, D Osses, D Nieboer, CH Bangma… - European urology, 2020 - Elsevier
Context Magnetic resonance imaging (MRI), with or without MRI-targeted biopsy (MRI
pathway), is an alternative test to systematic transrectal ultrasonography-guided biopsy in …

Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use

JO Barentsz, JC Weinreb, S Verma… - European …, 2015 - pmc.ncbi.nlm.nih.gov
Rapid technical advances have enabled multiparametric magnetic resonance imaging
(mpMRI) combined with magnetic resonance (MR)–targeted biopsy to become valuable …

Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging

DC Johnson, SS Raman, SA Mirak, L Kwan… - European urology, 2019 - Elsevier
Background Multiparametric magnetic resonance imaging (mpMRI) undoubtedly affects the
diagnosis and treatment of localized prostate cancer (CaP). However, clinicians need a …

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

H Grönberg, J Adolfsson, M Aly, T Nordström… - The lancet …, 2015 - thelancet.com
Background The prostate-specific antigen (PSA) test is used to screen for prostate cancer
but has a high false-positive rate that translates into unnecessary prostate biopsies and …